SANUWAVE’s CE-marked orthoPACE devices sold fewer units in 2012, partially due to the European economic downturn, according to the release.
The company’s research and development cost $1.8 million over the past year compared with $2.7 million in 2011, a 35 percent decrease, due to lower clinical results expenses.
More Articles on Devices:
7 New Orthopedic Device Launches & Releases
Amedica Valeo Interbody Fusion Device Hits 10k Implantations
Baptist Medical Center Acquires Renaissance Spine System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
